Monthly Archives: May 2024

In a 1st, scientist grow mini brains with functional blood-brain barriers – Livescience.com

Posted: May 27, 2024 at 2:49 am

For the first time, scientists have grown miniature models of the human brain that incorporate the organ's built-in security system.

The roughly sesame seed-size models include functional blood-brain barriers (BBB). In a full-size brain, the BBB would protect the delicate organ from potentially harmful substances that might be circulating through the rest of the body.

"Lack of an authentic human BBB model has been a major hurdle in studying neurological diseases," study co-author Ziyuan Guo, a neurobiologist and stem cell scientist at Cincinnati Children's Hospital Medical Center, said in a statement. "This is an important advance because animal models we currently use in research do not accurately reflect human brain development and BBB functionality."

Guo and his colleagues described their tiny, BBB-carrying brain models in a recent study, published May 15 in the journal Cell Stem Cell.

Related: Lab-grown minibrains will be used as 'biological hardware' to create new biocomputers, scientists propose

In the body, the BBB lines blood vessels that pass through the brain and allows only some substances through, such as hormones and glucose, while blocking out threats, such as toxins and bacteria. It also blocks out many medicines, which poses a challenge for drug developers working on treatments for brain diseases.

The new, lab-grown models combine cerebral organoids 3D clusters of brain cells grown from stem cells with blood-vessel organoids, which are also grown from stem cells but resemble vasculature in the body. Together, these two types of organoids form what the researchers call "assembloids," which simulate how maturing brain and blood vessel cells grow and interact with one another.

Get the worlds most fascinating discoveries delivered straight to your inbox.

The study showed that, about a month after being combined, the two types of organoids merged together into spherical structures that each measured about the size of a sesame seed. The culture that supports the growth and merger of the two organoids must be carefully controlled, and a physical gel matrix acts as a scaffolding to help support the assembloids, Guo told Live Science in an email.

As proof-of-concept for how these models might be used, the researchers grew assembloids with cells from patients with a cerebral cavernous malformation, meaning a cluster of abnormally shaped blood vessels in their nervous system. These malformations sometimes arise from genetic mutations and can cause symptoms that lead to serious complications, such as stroke and seizure.

The researchers' assembloids captured cellular features seen in people with cerebral cavernous malformations, "offering new insights into the underlying molecular and cellular pathology of cerebral vascular disorders," Guo said in the statement.

In the team's initial tests, the BBB assembloids can be grown for up to five months, or potentially longer, but this hasn't been tested, he added in an email. Four to five months of growth corresponds with roughly the second semester of brain development in the womb.

In the future, the team aims to grow similar assembloids using stem cells from people with different brain diseases, so that the final models would reflect the underlying biology of those conditions.

And more broadly, such assembloids could not only be used to study brain diseases but also to test new drugs, investigate how toxins injure the brain and BBB and reveal novel strategies for delivering medicines through the BBB.

"BBB assembloids represent a game-changing technology with broad implications for neuroscience, drug discovery, and personalized medicine," Guo said in the statement.

Editor's note: This story was updated shortly after publishing with additional quotes from Guo.

Ever wonder why some people build muscle more easily than others or why freckles come out in the sun? Send us your questions about how the human body works to community@livescience.com with the subject line "Health Desk Q," and you may see your question answered on the website!

The rest is here:
In a 1st, scientist grow mini brains with functional blood-brain barriers - Livescience.com

Posted in Stem Cells | Comments Off on In a 1st, scientist grow mini brains with functional blood-brain barriers – Livescience.com

Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells – Nature.com

Posted: May 27, 2024 at 2:49 am

Laurenti, E. & Gottgens, B. From haematopoietic stem cells to complex differentiation landscapes. Nature 553, 418426 (2018).

Article CAS PubMed PubMed Central Google Scholar

Bauer, T. R. Jr. et al. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. Blood 108, 33133320 (2006).

Article CAS PubMed PubMed Central Google Scholar

Blaese, R. M. et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4years. Science 270, 475480 (1995).

Article CAS PubMed Google Scholar

Boztug, K. et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 19181927 (2010).

Article CAS PubMed PubMed Central Google Scholar

Cowan, M. J. et al. Early outcome of a phase I/II clinical trial (NCT03538899) of gene-corrected autologous CD34+ hematopoietic cells and low-exposure busulfan in newly diagnosed patients with Artemis-deficient severe combined immunodeficiency (ART-SCID). Biol. Blood Marrow Transpl. 26, S88S89 (2020).

Article Google Scholar

Gaspar, H. B. et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 21812187 (2004).

Article CAS PubMed Google Scholar

Kanter, J. et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N. Engl. J. Med. 386, 617628 (2022).

Article CAS PubMed Google Scholar

Kohn, L. A. & Kohn, D. B. Gene therapies for primary immune deficiencies. Front. Immunol. 12, 648951 (2021).

Article CAS PubMed PubMed Central Google Scholar

Kondo, M. et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev. Immunol. 21, 759806 (2003).

Article CAS PubMed Google Scholar

Locatelli, F. et al. Betibeglogene autotemcel gene therapy for non-0/0 genotype -thalassemia. N. Engl. J. Med. 386, 415427 (2022).

Article CAS PubMed Google Scholar

Malech, H. L. et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl Acad. Sci. USA 94, 1213312138 (1997).

Article CAS PubMed PubMed Central Google Scholar

Morgan, R. A., Gray, D., Lomova, A. & Kohn, D. B. Hematopoietic stem cell gene therapy: progress and lessons learned. Cell Stem Cell 21, 574590 (2017).

Article CAS PubMed PubMed Central Google Scholar

Sago, C. D. et al. Nanoparticles that deliver RNA to bone marrow identified by in vivo directed evolution. J. Am. Chem. Soc. 140, 1709517105 (2018).

Article CAS PubMed PubMed Central Google Scholar

Shi, D., Toyonaga, S. & Anderson, D. G. In vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles. Nano Lett. 23, 29382944 (2023).

Article CAS PubMed PubMed Central Google Scholar

Sou, K., Goins, B., Oyajobi, B. O., Travi, B. L. & Phillips, W. T. Bone marrow-targeted liposomal carriers. Expert Opin. Drug Deliv. 8, 317328 (2011).

Article CAS PubMed PubMed Central Google Scholar

Sou, K., Klipper, R., Goins, B., Tsuchida, E. & Phillips, W. T. Circulation kinetics and organ distribution of Hb-vesicles developed as a red blood cell substitute. J. Pharmacol. Exp. Ther. 312, 702709 (2005).

Article CAS PubMed Google Scholar

Xue, L. et al. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment. J. Am. Chem. Soc. 144, 99269937 (2022).

Article CAS PubMed Google Scholar

Boulais, P. E. & Frenette, P. S. Making sense of hematopoietic stem cell niches. Blood 125, 26212629 (2015).

Article CAS PubMed PubMed Central Google Scholar

Ikonomi, N., Kuhlwein, S. D., Schwab, J. D. & Kestler, H. A. Awakening the HSC: dynamic modeling of HSC maintenance unravels regulation of the TP53 pathway and quiescence. Front. Physiol. 11, 848 (2020).

Article PubMed PubMed Central Google Scholar

Li, J. Quiescence regulators for hematopoietic stem cell. Exp. Hematol. 39, 511520 (2011).

Article PubMed Google Scholar

Man, Y., Yao, X., Yang, T. & Wang, Y. Hematopoietic stem cell niche during homeostasis, malignancy, and bone marrow transplantation. Front. Cell Dev. Biol. 9, 621214 (2021).

Article PubMed PubMed Central Google Scholar

Nakamura-Ishizu, A., Takizawa, H. & Suda, T. The analysis, roles and regulation of quiescence in hematopoietic stem cells. Development 141, 46564666 (2014).

Article CAS PubMed Google Scholar

Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 10861093 (2011).

Article CAS PubMed Google Scholar

Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645648 (1994).

Article CAS PubMed Google Scholar

Mandal, T., Beck, M., Kirsten, N., Linden, M. & Buske, C. Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles. Sci. Rep. 8, 989 (2018).

Article PubMed PubMed Central Google Scholar

Pei, S. & Jordan, C. T. How close are we to targeting the leukemia stem cell? Best Pract. Res. Clin. Haematol. 25, 415418 (2012).

Article CAS PubMed Google Scholar

Li, C. et al. Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models. Cancer Res. 80, 549560 (2020).

Article CAS PubMed Google Scholar

Li, C. et al. In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal globin in beta-YAC mice. Blood Adv. 5, 11221135 (2021).

Article CAS PubMed PubMed Central Google Scholar

Li, C. et al. In vivo HSC gene therapy using a bi-modular HDAd5/35++ vector cures sickle cell disease in a mouse model. Mol. Ther. 29, 822837 (2021).

Article CAS PubMed Google Scholar

Li, C. et al. Safe and efficient in vivo hematopoietic stem cell transduction in nonhuman primates using HDAd5/35++ vectors. Mol. Ther. Methods Clin. Dev. 24, 127141 (2022).

Article PubMed Google Scholar

Psatha, N. et al. Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo. Blood 138, 15401553 (2021).

Article CAS PubMed PubMed Central Google Scholar

Muruve, D. A., Barnes, M. J., Stillman, I. E. & Libermann, T. A. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10, 965976 (1999).

Article CAS PubMed Google Scholar

Sweeney, C. L. & De Ravin, S. S. The promise of in vivo HSC prime editing. Blood 141, 20392040 (2023).

Article CAS PubMed Google Scholar

Worgall, S., Wolff, G., Falck-Pedersen, E. & Crystal, R. G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8, 3744 (1997).

Article CAS PubMed Google Scholar

Lek, A. et al. Death after high-dose rAAV9 gene therapy in a patient with Duchennes muscular dystrophy. N. Engl. J. Med. 389, 12031210 (2023).

Article CAS PubMed Google Scholar

Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 10781094 (2021).

Article CAS PubMed PubMed Central Google Scholar

Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313320 (2020).

Article CAS PubMed PubMed Central Google Scholar

Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).

Article CAS PubMed PubMed Central Google Scholar

Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282300 (2023).

Article CAS PubMed PubMed Central Google Scholar

Farbiak, L. et al. All-in-one dendrimer-based lipid nanoparticles enable precise HDR-mediated gene editing in vivo. Adv. Mater. 33, e2006619 (2021).

Article PubMed PubMed Central Google Scholar

Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat. Mater. 20, 701710 (2021).

Article CAS PubMed PubMed Central Google Scholar

Liu, S. et al. Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes. J. Am. Chem. Soc. 143, 2132121330 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wang, X. et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat. Protoc. 18, 265291 (2023).

Article CAS PubMed Google Scholar

Wei, T., Cheng, Q., Min, Y. L., Olson, E. N. & Siegwart, D. J. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat. Commun. 11, 3232 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhang, D. et al. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat. Nanotechnol. 17, 777787 (2022).

Article CAS PubMed PubMed Central Google Scholar

Wu, L. C. et al. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108, 11831188 (2006).

Article CAS PubMed PubMed Central Google Scholar

Metais, J. Y. et al. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv. 3, 33793392 (2019).

Article PubMed PubMed Central Google Scholar

Newby, G. A. et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature 595, 295302 (2021).

Article CAS PubMed PubMed Central Google Scholar

Stavropoulou, V., Peters, A. & Schwaller, J. Aggressive leukemia driven by MLL-AF9. Mol. Cell Oncol. 5, e1241854 (2018).

Article PubMed Google Scholar

Hou, X. et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat. Nanotechnol. 15, 4146 (2020).

Article CAS PubMed PubMed Central Google Scholar

See the rest here:
Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells - Nature.com

Posted in Stem Cells | Comments Off on Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells – Nature.com

Past, present, and future of cell replacement therapy for parkinson’s disease: a novel emphasis on host immune … – Nature.com

Posted: May 27, 2024 at 2:49 am

Fahn, S. The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future. Parkinsonism Relat. Disord. 46, S1S5 (2018).

Article PubMed Google Scholar

Kalia, L. V. & Lang, A. E. Parkinsons disease. Lancet 386, 896912 (2015).

Article CAS PubMed Google Scholar

Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Primers 3, 17013 (2017).

Article PubMed Google Scholar

Obeso, J. A. et al. Missing pieces in the Parkinsons disease puzzle. Nat. Med. 16, 653661 (2010).

Article CAS PubMed Google Scholar

Meissner, W. G. et al. Priorities in Parkinsons disease research. Nat. Rev. Drug Discov. 10, 377393 (2011).

Article CAS PubMed Google Scholar

Barker, R. A., Barrett, J., Mason, S. L. & Bjorklund, A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinsons disease. Lancet Neurol. 12, 8491 (2013).

Article CAS PubMed Google Scholar

Sonntag, K. C. et al. Pluripotent stem cell-based therapy for Parkinsons disease: Current status and future prospects. Prog. Neurobiol. 168, 120 (2018).

Article PubMed PubMed Central Google Scholar

Parmar, M., Grealish, S. & Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci. 21, 103115 (2020).

Article CAS PubMed Google Scholar

Barker, R. A., Drouin-Ouellet, J. & Parmar, M. Cell-based therapies for Parkinson disease-past insights and future potential. Nat. Rev. Neurol. 11, 492503 (2015).

Article CAS PubMed Google Scholar

Skidmore, S. & Barker, R. A. Challenges in the clinical advancement of cell therapies for Parkinsons disease. Nat. Biomed. Eng. 7, 370386 (2023).

Article PubMed PubMed Central Google Scholar

Cha, Y., Park, T. Y., Leblanc, P. & Kim, K. S. Current status and future perspectives on stem cell-based therapies for Parkinsons disease. J. Mov. Disord. 16, 2241 (2023).

Article PubMed PubMed Central Google Scholar

Lindvall, O. Clinical translation of stem cell transplantation in Parkinsons disease. J. Intern. Med. 279, 3040 (2016).

Article CAS PubMed Google Scholar

Li, J. Y. & Li, W. Postmortem studies of fetal grafts in Parkinsons Disease: What lessons have we learned? Front. Cell. Dev. Biol. 9, 666675 (2021).

Article PubMed PubMed Central Google Scholar

Lindvall, O. et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinsons disease. Science 247, 574577 (1990).

Article CAS PubMed Google Scholar

Defer, G. L. et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 119, 4150 (1996).

Article PubMed Google Scholar

Mendez, I. et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J. Neurosurg. 96, 589596 (2002).

Article PubMed Google Scholar

Peschanski, M. et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinsons disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117, 487499 (1994).

Article PubMed Google Scholar

Freed, C. R. et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinsons disease. N. Engl. J. Med. 327, 15491555 (1992).

Article CAS PubMed Google Scholar

Freeman, T. B. et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinsons disease. Ann. Neurol. 38, 379388 (1995).

Article CAS PubMed Google Scholar

Hagell, P. et al. Sequential bilateral transplantation in Parkinsons disease: Effects of the second graft. Brain 122, 11211132 (1999).

Article PubMed Google Scholar

Kefalopoulou, Z. et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: Two case reports. JAMA Neurol. 71, 8387 (2014).

Article PubMed PubMed Central Google Scholar

Kordower, J. H. et al. Functional fetal nigral grafts in a patient with Parkinsons disease: chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370, 203230 (1996).

Article CAS PubMed Google Scholar

Kordower, J. H. et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinsons disease. Mov. Disord. 13, 383393 (1998).

Article CAS PubMed Google Scholar

Lindvall, O. et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinsons disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46, 615631 (1989).

Article CAS PubMed Google Scholar

Lindvall, O. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinsons disease. Ann. Neurol. 35, 172180 (1994).

Article CAS PubMed Google Scholar

Lindvall, O. et al. Transplantation of fetal dopamine neurons in Parkinsons disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol. 31, 155165 (1992).

Article CAS PubMed Google Scholar

Mendez, I. et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinsons disease. Brain 128, 14981510 (2005).

Article PubMed Google Scholar

Piccini, P. et al. Dopamine release from nigral transplants visualized in vivo in a Parkinsons patient. Nat. Neurosci. 2, 11371140 (1999).

Article CAS PubMed Google Scholar

Spencer, D. D. et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinsons disease. N. Engl. J. Med. 327, 15411548 (1992).

Article CAS PubMed Google Scholar

Wenning, G. K. et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinsons disease. Ann. Neurol. 42, 95107 (1997).

Article CAS PubMed Google Scholar

Widner, H. et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 327, 15561563 (1992).

Article CAS PubMed Google Scholar

Li, W. et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc. Natl. Acad. Sci. USA 113, 65446549 (2016).

Article CAS PubMed PubMed Central Google Scholar

Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinsons disease. Nat. Med. 14, 504506 (2008).

Article CAS PubMed Google Scholar

Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinsons disease suggest host-to-graft disease propagation. Nat. Med. 14, 501503 (2008).

Article CAS PubMed Google Scholar

Mendez, I. et al. Dopamine neurons implanted into people with Parkinsons disease survive without pathology for 14 years. Nat. Med. 14, 507509 (2008).

Article CAS PubMed PubMed Central Google Scholar

Greene, P. E. et al. Persistent dyskinesias in patients with fetal tissue transplantation for Parkinson disease. NPJ Parkinsons Dis. 7, 38 (2021).

Article CAS PubMed PubMed Central Google Scholar

Freed, C. R. et al. Transplantation of embryonic dopamine neurons for severe Parkinsons disease. N. Engl. J. Med. 344, 710719 (2001).

Article CAS PubMed Google Scholar

Olanow, C. W. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinsons disease. Ann. Neurol. 54, 403414 (2003).

Article PubMed Google Scholar

Thompson, L. & Bjorklund, A. Survival, differentiation, and connectivity of ventral mesencephalic dopamine neurons following transplantation. Prog. Brain Res. 200, 6195 (2012).

Article PubMed Google Scholar

Ramachandran, A. C., Bartlett, L. E. & Mendez, I. M. A multiple target neural transplantation strategy for Parkinsons disease. Rev. Neurosci. 13, 243256 (2002).

Article PubMed Google Scholar

Castilho, R. F., Hansson, O. & Brundin, P. Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinsons disease. Prog. Brain Res. 127, 203231 (2000).

Article CAS PubMed Google Scholar

Bjorklund, A. & Kordower, J. H. Cell therapy for Parkinsons disease: what next? Mov. Disord. 28, 110115 (2013).

Article CAS PubMed Google Scholar

Brundin, P. et al. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transpl. 9, 179195 (2000).

Article CAS Google Scholar

Brundin, P. et al. Human fetal dopamine neurons grafted in a rat model of Parkinsons disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release. Exp. Brain Res. 70, 192208 (1988).

Article CAS PubMed Google Scholar

Frodl, E. M., Duan, W. M., Sauer, H., Kupsch, A. & Brundin, P. Human embryonic dopamine neurons xenografted to the rat: effects of cryopreservation and varying regional source of donor cells on transplant survival, morphology and function. Brain Res. 647, 286298 (1994).

Article CAS PubMed Google Scholar

Barker, R. A., Dunnett, S. B., Faissner, A. & Fawcett, J. W. The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Exp. Neurol. 141, 7993 (1996).

Article CAS PubMed Google Scholar

Duan, W. M., Widner, H. & Brundin, P. Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in rats. Exp. Brain Res. 104, 227242 (1995).

Article CAS PubMed Google Scholar

Emgard, M., Karlsson, J., Hansson, O. & Brundin, P. Patterns of cell death and dopaminergic neuron survival in intrastriatal nigral grafts. Exp. Neurol. 160, 279288 (1999).

Article CAS PubMed Google Scholar

Wenker, S. D. & Pitossi, F. J. Cell therapy for Parkinsons disease is coming of age: current challenges and future prospects with a focus on immunomodulation. Gene Ther. 27, 614 (2020).

Article CAS PubMed Google Scholar

Zawada, W. M. et al. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res. 786, 96103 (1998).

Article CAS PubMed Google Scholar

Read this article:
Past, present, and future of cell replacement therapy for parkinson's disease: a novel emphasis on host immune ... - Nature.com

Posted in Stem Cells | Comments Off on Past, present, and future of cell replacement therapy for parkinson’s disease: a novel emphasis on host immune … – Nature.com

PhD Candidate within Molecular Medicine job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY – NTNU … – Times Higher Education

Posted: May 27, 2024 at 2:49 am

About the job

We have vacancy for one PhD candidate at theOtterlei groupat the Department of Clinical and Molecular Medicine. The project addresses the need for new antibiotics with novel mechanisms of action and new treatment regimens to handle the emerging antimicrobial resistance (AMR).

Based on knowledge of peptides with antibacterial activities and conserved mechanisms for mutagenesis, we have designed synthetic peptides with strong anti-mutagenic, antibacterial and anti-biofilm activities. These peptides interfere with DNA translesion synthesis (i.e. mutagenesis), bacterial replication, and cellular signalling, and is targeting the bacterial DNA sliding clamp, the b-clamp. The project specifically focuses on development of second-generation antibacterial peptides. This project is part of a multidisciplinary collaboration project (TAMiR - NTNU) between two faculties at NTNU, University of Oslo / Oslo University Hospitaland University of Copenhagen and cover competences from basic molecular microbiology, chemical synthesis and structural biology/modelling, bioinformatics, cell biology and immunology/infectious diseases.

The PhD candidate will study antimicrobial activities of the peptides using several different methods used in medical microbiology and evaluate the toxicity of the peptides in cell line based assays as well as initial toxicity studies in animals.

Required selection criteria

The PhD-position's main objective is to qualify for work in research positions. The qualification requirement is that you have completed a masters degree or second degree (equivalent to 120 credits) with a strong academic background in biochemistry, microbiology, molecular and cell biology or equivalent education with a grade of B or better in terms ofNTNUs grading scale. If you do not have letter grades from previous studies, you must have an equally good academic foundation. If you are unable to meet these criteria you may be considered only if you can document that you are particularly suitable for education leading to a PhD degree.

Master's students can apply, but the master's degree must be obtained and documented by the end of june 2024.

The appointment is to be made in accordance withRegulations on terms of employment for positions such as postdoctoral fellow, Phd candidate, research assistant and specialist candidateandRegulations concerning the degrees ofPhilosophiaeDoctor (PhD)andPhilosodophiaeDoctor (PhD) in artistic researchnational guidelines for appointment as PhD, post doctor and research assistant

Preferred selection criteria

Personal characteristics

In the evaluation of which candidate is best qualified, emphasis will be placed on education, experience and personal suitability.

We offer

Salary and conditions

As a PhD candidate (code 1017) you are normally paid from gross NOK 532200 per annum before tax, depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

The period of employment is 3years.

Appointment to a PhD position requires that you are admitted to thePhD programme in Medicine and Health Scienceswithin three months of employment, and that you participate in an organized PhD programme during the employment period.

The engagement is to be made in accordance with the regulations in force concerningState Employees and Civil Servants, and the acts relating to Control of the Export of Strategic Goods, Services and Technology. Candidates who by assessment of the application and attachment are seen to conflict with the criteria in the latter law will be prohibited from recruitment to NTNU. After the appointment you must assume that there may be changes in the area of work.

It is a prerequisite you can be present at and accessible to the institution on a daily basis.

About the application

The application and supporting documentation to be used as the basis for the assessment must be in English.

Publications and other scientific work must be attached to the application. Please note that your application will be considered based solely on information submitted by the application deadline. You must therefore ensure that your application clearly demonstrates how your skills and experience fulfil the criteria specified above.

The application must include:

If all,or parts,of your education has been taken abroad, we also ask you to attach documentation of the scope and quality of your entire education, both bachelor's and master's education, in addition to other higher education. Description of the documentation required can befoundhere. If you already have a statement fromNOKUT,pleaseattachthisas well.

We will take joint work into account. If it is difficult to identify your efforts in the joint work, you must enclose a short description of your participation.

NTNU is committed to following evaluation criteria for research quality according toThe San Francisco Declaration on Research Assessment - DORA.

General information

Working at NTNU

NTNU believes that inclusion and diversity is our strength. We want to recruit people with different competencies, educational backgrounds, life experiences and perspectives to contribute to solving our social responsibilities within education and research. We will facilitate for our employees needs.

The city of Trondheimis a modern European city with a rich cultural scene. Trondheim is the innovation capital of Norway with a population of 200,000. The Norwegian welfare state, including healthcare, schools, kindergartens and overall equality, is probably the best of its kind in the world. Professional subsidized day-care for children is easily available. Furthermore, Trondheim offers great opportunities for education (including international schools) and possibilities to enjoy nature, culture and family life and has low crime rates and clean air quality.

As an employeeatNTNU, you must at all times adhere to the changes that the development in the subject entails and the organizational changes that are adopted.

A public list of applicants with name, age, job title and municipality of residence is prepared after the application deadline. If you want to reserve yourself from entry on the public applicant list, this must be justified. Assessment will be made in accordance withcurrent legislation. You will be notified if the reservation is not accepted.

If you have any questions about the position, please contact Professor Marit Otterlei, telephone +47 72573075, emailmarit.otterlei@ntnu.no. If you have any questions about the recruitment process, please contact Vebjrn F. Andreassen, e-mail: vebjorn.andreassen@ntnu.no

If you think this looks interesting and in line with your qualifications, please submit your application electronically via jobbnorge.no with your CV, diplomas and certificates attached. Applications submitted elsewhere will not be considered. Upon request, you must be able to obtain certified copies of your documentation.

Application deadline: 10.06.2024

NTNU - knowledge for a better world

The Norwegian University of Science and Technology (NTNU) creates knowledge for a better world and solutions that can change everyday life.

The Department of Clinical and Molecular Medicine (IKOM):

The Department of Clinical and Molecular Medicine (IKOM) is NTNUs largest department, with 450 employees. Our research and teaching help to improve treatment and health.

IKOM has expertise in basic, clinical and translational research within broad disciplinary areas. We study childrens and womens health, cancers, blood disorders and infectious diseases, gastroenterology, inflammation, metabolic disorders, laboratory sciences and medical ethics. The Department offers teaching in medicine at masters and PhD level. We also offer continuing education for employees in the health services.

Deadline10th June 2024 EmployerNTNU - Norwegian University of Science and Technology MunicipalityTrondheim ScopeFulltime Duration Project Place of serviceErling Skjalgssons gate 1, 7030 Trondheim

Continue reading here:
PhD Candidate within Molecular Medicine job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU ... - Times Higher Education

Posted in Molecular Medicine | Comments Off on PhD Candidate within Molecular Medicine job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY – NTNU … – Times Higher Education

2024: Prof Eugenia Piddini Medical Sciences Fellow | School of Cellular and Molecular Medicine – University of Bristol

Posted: May 27, 2024 at 2:49 am

Professor Eugenia Piddini has been elected to the Academy of Medical Sciences respected and influential Fellowship. She joins 58 exceptional biomedical and health scientists selected for their exceptional contributions to the advancement of medical science.

The newFellows, announced on Tuesday 21 May, have been recognised for their remarkable contributions to advancing biomedical and health sciences, groundbreaking research discoveries and translating developments into benefits for patients and wider society.

Awardees join an esteemed Fellowship of over 1,400 researchers who are at the heart of the Academy's work, which includes nurturing the next generation of researchers and shaping research and health policy in the UK and worldwide. The expertise of Fellows elected this year spans a wide range of clinical and non-clinical disciplines, from midwifery to cancer stem cell biology.

Eugenia Piddini,Professor of Cell Biology in theSchool of Cellular and Molecular Medicine, is conducting innovative work to identify cell competition-based strategies to gain control over tissue colonisation, its impact in tissue colonisation in regenerative medicine and to prevent tumour expansion in cancer.

A cell and developmental biologist,Eugenia is known for her seminal work in the field of cell competition the mechanism of tissue quality control that removes damaged cells from tissues. Eugenias discoveries have helped widen the scope of cell competition in terms of physiological relevance and potential therapeutic impact. Recently, Eugenias group demonstrated that cell competition acts in adult tissues. There it can potentially slow down the onset of disease/ageing by eliminating damaged cells.

Eugenias team has also shown that tumour cells kill surrounding normal cells via cell competition to free space for their own growth. Their work has identified many mechanisms and signals that cells use to compete. By explaining the mechanisms that cells use to compete the Piddini group aims to identify cell competition-based strategies to gain control over tissue colonisation.

In recognition of her work Eugenia, who is also School Research Director, was awarded theBritish Society for Cell Biology Hooke Medalin 2019 and in 2023, was elected as aMember of the European Molecular Biology Organisation.

Alongside Professor Piddini, Professor Gene Feder OBE, has also been elected from the University. Gene Feder,is a GP and Professor of Primary Care at BristolsCentre for Academic Primary Care, Bristol Medical School and Director of VISION, aUK Prevention Research Partnership(UKPRP) consortium.

Professor Andrew Morris PMedSci, President of theAcademy of Medical Sciences, said: It is an honour to welcome these brilliant minds to our Fellowship. Our new Fellows lead pioneering work in biomedical research and are driving remarkable improvements in healthcare. We look forward to working with them, and learning from them, in our quest to foster an open and progressive research environment that improves the health of people everywhere through excellence in medical science.

This year's cohort marks a significant milestone in the Academy's efforts to promote equality, diversity and inclusion (EDI) within its Fellowship election. Among the new Fellows, 41 per cent are women, the highest percentage ever elected. Additionally, Black, Asian and minority ethnic representation is 29 per cent, an 11 per cent increase from the previous year. The new Fellows hold positions at institutions across the UK, including in Edinburgh, Birmingham, Liverpool, Manchester, Sheffield, Nottingham and York.

Professor Morris added: It is also welcoming to note that this year's cohort is our most diverse yet, in terms of gender, ethnicity and geography. While this progress is encouraging, we recognise that there is still much work to be done to truly diversify our Fellowship. We remain committed to our EDI goals and will continue to take meaningful steps to ensure our Fellowship reflects the rich diversity of the society we serve."

The new Fellows will be formally admitted to the Academy at a ceremony on Wednesday 18 September 2024.

The Academy of Medical Sciences is the independent, expert body representing the diversity of medical science in the UK. Its mission is to advance biomedical and health research and its translation into benefits for society. The Academy's elected Fellows are the most influential scientists in the UK and worldwide, drawn from the NHS, academia, industry and the public service.

About theAcademy of Medical SciencesTheAcademy of Medical Sciencesis the independent, expert voice of biomedical and health research in the UK. Our Fellowship comprises the most influential scientists in the UK and worldwide, drawn from the NHS, academia, industry, and the public service. Our mission is to improve the health of people everywhere by creating an open and progressive research sector. We do this by working with patients and the public to influence policy and biomedical practice, strengthening UK biomedical and health research, supporting the next generation of researchers through funding and career development opportunities, and working with partners globally.

See the rest here:
2024: Prof Eugenia Piddini Medical Sciences Fellow | School of Cellular and Molecular Medicine - University of Bristol

Posted in Molecular Medicine | Comments Off on 2024: Prof Eugenia Piddini Medical Sciences Fellow | School of Cellular and Molecular Medicine – University of Bristol

Radar Therapeutics Raises $13.4M in Seed Funding to Develop Smart Programmable Medicines Using Molecular … – BioSpace

Posted: May 27, 2024 at 2:49 am

BERKELEY, Calif.--(BUSINESS WIRE)-- Radar Therapeutics, a biotech company developing smart programmable medicines, today announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio. Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined the round, with participation from PearVC, BEVC and other investors. The financing will support advancement of Radars internal programs, team expansion and partnering.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523395742/en/

Radar Therapeutics founders Sophia Lugo, CEO and Eerik Kaseniit, PhD, CSO & President. Photo credit: Radar Therapeutics

Current genetic medicines, including mRNA therapeutics, are not targeted and typically rely on cell surface proteins to confer targeting, which limits application. This often means that ex vivo cell therapies, where genetic material is introduced outside of the body, have to be used.

Radar is developing programmable genetic and mRNA-based therapeutics that use RNA sensors mRNAs that gate their expression based on other RNAs in the cell for specific payload expression to deliver targeted, timed delivery of the drug payload into the right cells at the right time. Controlled translation of the mRNA therapy avoids systemic toxic side-effects in non-target cells. The RADAR platform enables "smart," rationally designed precision therapeutics.

With Radars technology, we can now precisely alter the biology of the cell, delete harmful cells, or potentially reprogram cells for autoimmune diseases. This has the potential to enable a new generation of safer, more durable and effective mRNA therapeutics for applications beyond vaccines, said synthetic biology pioneer Jim Collins, Ph.D., Co-Founder at Radar Therapeutics and the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT.

Creating genetic expression-regulation systems that operate at the level of translation while being programmable to ensure compatibility with next-generation mRNA-based medicines has been a long-lived dream, said Xiaojing Gao, Ph.D., Associate Professor of Chemical Engineering at Stanford and Radar Co-Founder.

Like a safety switch, our payload is always off, and only gets turned on in the right cell, said Sophia Lugo, CEO & Co-Founder, Radar Therapeutics. We can selectively write a function into any cell type. Programmable mRNA-based therapies have the potential to be in vivo, scalable and modular, to improve patient access. Were thrilled to have the support of these top-tier investors as we advance our preclinical programs.

Unlike approaches using microRNAs to turn payload expression off in predefined cells, Radar's technology enables the activation of protein expression in desired cells, said Eerik Kaseniit, Ph.D., Chief Scientific Officer & Co-Founder, Radar Therapeutics. Were leveraging the explosion in single-cell transcriptomic data, and advances in our understanding of RNA-editing enzymes such as ADAR, to design simple switches to create smart mRNA therapies. Weve assembled a world class team to push the platform towards product and are excited to use these funds to grow the team further.

Radar's focus on full transcriptomic analysis sets them apart from traditional targeting methods that rely solely on cell surface markers, said Omri Drory, PhD, Partner, NfX Ventures. By leveraging a broad dataset offered by single-cell transcriptomics, Radar can precisely identify cellular signatures and engineer programmable therapies accordingly, offering unparalleled specificity to avoid off-target effects.

A publication in Nature Biotechnology describes the design of a highly specific, compact sensor sequence to the driver RNAs or disease markers of a cell of interest, including a stop codon in front of the mRNA payload. In non-target cells without the marker RNAs, the payload is not expressed due to the stop codon, which prevents ribosomal translation. In target cells, the stop codon is selectively removed through interactions with cell-type-defining marker RNAs.

Radar Therapeutics is advancing this technology even further by developing a proprietary methodology that only uses endogenous enzymes to achieve high expression levels, which is a significant advancement in the field of RNA editing, as it will potentially enable the development of safer, more effective, and cost-efficient therapies for various diseases.

The companys scientific advisory board includes: Xiaojing Gao, Ph.D., Co-Founder, James J. Collins, Ph.D., Co-Founder, David Schaffer, PhD., Eric Klein, M.D., and Svetlana Lucas, PhD.

Radar has received a number of industry awards including: Abbvie Golden Ticket, J&J West Coast Cell and Gene Therapy Symposium "Judge's Choice" award, and an Amgen Diversity, Inclusion and Belonging Award.

About Radar Therapeutics

Radar Therapeutics is a biotech company developing programmable precision therapeutics. Leveraging innovative mRNA technology and proprietary regulatory control elements, the company aims to revolutionize medicine by enabling targeted, timely, and controlled therapeutic interventions. Radar is committed to advancing the boundaries of genetic medicine to address unmet medical needs and improve patient access. The company is based in Berkeley, CA. For more information, visit http://www.radartx.bio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523395742/en/

Excerpt from:
Radar Therapeutics Raises $13.4M in Seed Funding to Develop Smart Programmable Medicines Using Molecular ... - BioSpace

Posted in Genetic medicine | Comments Off on Radar Therapeutics Raises $13.4M in Seed Funding to Develop Smart Programmable Medicines Using Molecular … – BioSpace

UN treaty to look at indigenous medicine, genetic resources in patents | Loop St. Lucia – Loop News St. Lucia

Posted: May 27, 2024 at 2:49 am

GENEVA (AP) UN member countries on Friday concluded a new treaty to help ensure that traditional knowledge about genetic resources, like medicines derived from exotic plants in the Andes mountains, is properly traced.

It marks the first time the 193 member states of the UN's World Intellectual Property Organization have reached agreement on patent protections about historic knowledge from indigenous cultures, which have long been exploited by colonists, traders and others.

The treaty doesn't address compensation to indigenous communities for their historic expertise about products drawn from things like from tropical plants.

But the accord is seen as an important first step. It requires patent applicants, like foreign entrepreneurs or international companies, to specify where they got ideas about what goes into their products, especially inputs drawn from the knowledge of indigenous or local peoples.

Daren Tang, the organization's director-general, said the agreement showed that "multilateralism is alive and well at WIPO."

"Today we made history in many ways," he said. "Through this, we are showing that the IP system can continue to incentivize innovation while evolving in a more inclusive way, responding to the needs of all countries and their communities."

The WIPO Intellectual Property, Genetic Resources and Associated Traditional Knowledge treaty, reached by consensus after more than two decades in the making, will take effect as international law after 15 countries adopt it.

The agreement centers on genetic resources like medicinal plants, crops from farms and some animal breeds. It will not be retroactive, meaning that it's only applicable to future discoveries, not past ones.

WIPO's rules don't allow for intellectual property protection of natural or genetic resources themselves but do help to safeguard inventions by people that put those resources to work for humankind, whether historically or recently.

The deal will, for example, require companies in industries like fashion, luxury goods and pharmaceuticals to specify the origin of the plant-based chemicals in medicines or plants in skin creams that they use for their products, if drawn from local knowledge.

See original here:
UN treaty to look at indigenous medicine, genetic resources in patents | Loop St. Lucia - Loop News St. Lucia

Posted in Genetic medicine | Comments Off on UN treaty to look at indigenous medicine, genetic resources in patents | Loop St. Lucia – Loop News St. Lucia

Hormone Replacement Therapy May Benefit Some Women with Pulmonary Hypertension – Managed Healthcare Executive

Posted: May 27, 2024 at 2:49 am

New evidence suggests the use of hormone replacement therapy (HRT) may lead to benefits in certain women with pulmonary hypertension. The findings add to a long debate over the role of hormones like estrogen in the course of the disease.

During a presentation at the American Thoracic Societys 2024 International Conference in San Diego, investigators said HRT appeared to improve pulmonary vascular disease and right ventricular (RV) function in a cohort of 742 women who participated in the study

Corresponding author Audriana Hurbon, M.D., of the University of Arizona College of Medicine, explained along with colleagues that previous research has indicated women with World Symposium Group 1 pulmonary hypertension have improved preservation of RV function compared to men in the same disease group. Yet, Hurbon and colleagues said it was not clear whether the preservation of RV function was linked with endogenous and/or exogenous exposure to female hormones, and it was not known if the apparent benefits of female hormones applied to all groups of pulmonary hypertension or merely to Group 1.

While it is accepted that in World Symposium Group 1 pulmonary hypertension female sex is associated with preservation of right ventricular function, the role of estrogen in pulmonary hypertension has been controversial, Hurbon explained, in a press release. Additionally, we know that women are affected by pulmonary hypertension more often than men, but when compared to each other, women seem to present less severely than men.

The more than 700 participants in Hurbons research were part of the National Heart Lung and Blood Institute-funded Pulmonary Vascular Disease Phenomics (PVDOMICS) Study. The women represented all five World Symposium disease groups, along with healthy controls and comparators who had risk factors for pulmonary hypertension but had not been diagnosed with the disease.

The authors set out to compare participants using mean pulmonary artery pressure on right heart catheterization to measure pulmonary vascular disease related to pulmonary hypertension, and characterizing RV function based on RV fractional shortening and RV ejection fraction from echocardiography.

Endogenous hormone exposure was quantified based on self-reported lifetime duration of menses. Participants were considered to have exogenous exposure to hormones if they had ever received HRT.

Hurbon and colleagues found that people with greater lifetime duration of menses had decreased average pulmonary arterial pressure regardless of which pulmonary hypertension group they belonged in. Specifically, they found mean pulmonary arterial pressure was 4714 mmHg for participants with 20-30 years of menses, versus 3713 mmHg for participants with more than 50 years of menses.

Additionally, participants who had taken HRT had lower mean pulmonary artery pressure (3511 vs 4214, P = 0.002) and pulmonary vascular resistance (53 vs 74, P = 0.006) and higher RV fractional shortening (3711 vs 329, P = 0.001) and RV ejection fraction (4813 vs 4012 %, P < 0.0001). However, when broken out by subgroup, the investigators only found statistically significant impacts in patients with Group 1 pulmonary hypertension.

Hurbon said in the press release that further analysis also suggests that older age and HRT exposure may have a positive synergistic effect.

This could support a theory suggesting a threshold of estrogen exposure necessary for a protective effect, she said.

The authors described their findings as preliminary, but they said their data suggest more research is needed to better understand the potential impacts of HRT, both positive and potentially negative, on patients with pulmonary hypertension.

We hope this study will be a catalyst for further exploration of the mechanisms of female reproductive hormones to identify therapeutic targets for right ventricular preservation in pulmonary hypertension, Hurbon said.

Read this article:
Hormone Replacement Therapy May Benefit Some Women with Pulmonary Hypertension - Managed Healthcare Executive

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy May Benefit Some Women with Pulmonary Hypertension – Managed Healthcare Executive

Weekend humor from Celia Rivenbark: Oh, so NOW hormone replacement is ok NC Newsline – NC Newsline

Posted: May 27, 2024 at 2:49 am

Hey ladies! Remember a few years ago when they said we shouldnt take hormone replacement therapy for menopause symptoms like hot flashes and night sweats? They said it was bad for you! It could give you cancer! Use guided imagery to power through those sweats and headaches and mood swings! Better to be safe than sorry.

Fun fact: Turns out the science wasnt nearly as sciency as we thought and some of us couldve skipped a decade of severe to moderate crazy-making unpleasantness. Now, they say its perfectly OK, and may even be better for you to take sensible doses of estrogen. (For the three men still reading, estrogen is Latin for Lord, dont let me kill my husband fore the house is paid for.)

Not only is hormone replacement making a comeback but also it turns out its GOOD FOR YOU. Your heart just loves it! When properly dosed, modern cocktails of HRT can swaddle your heart in protective goodness AND protect against bone loss!

Mmmmkay.

Ima need to speak to someone right now. RIGHT FRIKKIN NOW. Wheres Cousin Eddy when you need him? Remember how he kidnapped Clark Griswolds miserly boss in Christmas Vacation and brought him to the Griswold home just so Clark could yell at him in person? Yeah, that would be kind of perfect. Get me the researcher who said reports of cancer and strokes were flawed. Ill wait.

Im righteously angry. The kind of angry that makes the oft-maligned Karen complaining about the degree of wilt in her Cobb salad seem downright quaint by comparison.

Whats next? Smoking is good for you? The tar and nicotine meet up inside your lungs and knit tiny sweater vests you can cough out and give as holiday gifts to your loved ones?

What about asbestos? Should I return to the 1950s-built house I grew up in and lick the exterior shingles because it will give me great eyesight and, interestingly, a useful third hand?

What about lead pipes and paint? Are those going to be OK, too? Will we learn that rather than causing learning disabilities and life-altering physical ailments lead is the secret ingredient in the Barefoot Contessas irresistible crispy-skinned roast chicken?

Speaking of food, remember how they told us not to eat eggs? And then they were OK. And then they werent. And then they wereIm not even sure anymore.

The new guidelines of HRT Okie Dokie (my term, not theirs) applies to women under 60. While Im happy for my sister-girls in their 50s, I hope they know theres a whole bunch of us who still have to apologize to a clerk at TJ Maxx who had the wretched misfortune to ask, again, if wed like to apply for a store credit card. There was NO reason to scream. Let alone scream Sure because apparently I look like I cant even afford the stuff in this GODFORSAKEN sea of sign art, gallon jars of pink Himalayan sea salt and garlic presses. So many, many garlic presses

Yes, we acted ugly because we had no estrogen. The stuff that had once plumped our skin, hydrated our parts and made us look at our spouses with more desire and less homicide.

To be sure, theyve done some important tweaking over the years to make HRT safer, like using patches instead of pills (greatly reduces risk of stroke) and keeping the recommendation to women under 60. (Apparently, the bad study had too many older women and yall know how we can be.)

Todays HRTs benefits outweigh the risks, they say. And thats great news for millions of women. Yay you. My generation toughed it out and now find ourselves on the other side, newly obsessed with digging in the dirt and subscribing to something called Britbox.

Just you wait.

Here is the original post:
Weekend humor from Celia Rivenbark: Oh, so NOW hormone replacement is ok NC Newsline - NC Newsline

Posted in Hormone Replacement Therapy | Comments Off on Weekend humor from Celia Rivenbark: Oh, so NOW hormone replacement is ok NC Newsline – NC Newsline

Global Hormone Replacement Therapy Research Report 2024: A $35+ Billion Market by 2032 – Industry Trends, Share … – GlobeNewswire

Posted: May 27, 2024 at 2:49 am

Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Global Hormone Replacement Therapy Market, Size, Forecast 2024-2032, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis" report has been added to ResearchAndMarkets.com's offering.

The global Hormone Replacement Therapy (HRT) market is experiencing significant growth, with an estimated value of US$ 20.91 Billion in 2023. A consistent compound annual growth rate (CAGR) of 6.18% is forecasted from 2024 to 2032, culminating in a market size of US$ 35.86 Billion by the end of the forecast period. This expansion is predominantly driven by an aging population, rising prevalence of menopausal symptoms, increased awareness, and advancements in hormone replacement products and therapies.

Women worldwide are increasingly experiencing menopausal symptoms and hormonal imbalances, compelling a growing need for effective HRT. The demand for HRT is bolstered by the projected worldwide population growth, indicating a substantial future market for hormone therapies. As reported by the NHSBSA Statistics and Data Science, England has seen a significant increase in prescribed HRT items, demonstrating the rising prominence of hormone replacement therapy in healthcare regimes.

Advancements and Trends

Continuous research and development, coupled with product approvals such as Ascendis Pharma A/S's SKYTROFA, are anticipated to further propel the hormone therapy market's growth. The increasing awareness of menopausal challenges in economies such as China and India is steadily translating into heightened market activity. Further, the surge in hormonal disorders is creating opportunities for market expansion, as effective treatments for symptoms like mood swings and reduced libido are sought after.

United States Market Analysis

The United States holds the leading position in the Hormone Replacement Therapy market, supported by an increase in therapy utilization among the target demographic and the continuous introduction of innovative drug delivery technologies. A significant portion of post-menopausal women in the US have utilized HRT, according to NIH. With a substantive patient population affected by conditions such as thyroid hormone imbalances, the market is set to maintain its robust growth trajectory.

Key Companies in the Market

The competitive landscape of the global Hormone Replacement Therapy market features key players including Abbott Laboratories, Bayer AG, Eli Lilly & Company, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Abbvie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd, and Dr. Reddys Laboratories Ltd. Recent developments such as FDA approvals and strategic partnerships accentuate these companies' commitment to meeting the growing demand for advanced HRT solutions.

Segments and Regional Insights

The global Hormone Replacement Therapy market encompasses various product types, disease types, routes of administration, and distribution channels. The market analysis includes segments like estrogen, human growth hormone, thyroid hormone, testosterone hormone, and progestogen replacement therapies. Additionally, the market explores different disease types and administrative routes along with distribution via hospital pharmacies, retail stores, and online pharmacies. The comprehensive market division also offers a granular view of HRT adoption patterns across a global spectrum covering North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The insights presented reflect the growing significance of Hormone Replacement Therapy and illustrate the market's future outlook in relation to demographic shifts, scientific advancements, and healthcare awareness. The global interest in achieving enhanced quality of life post-menopause and managing hormonal disorders underlines the importance of HRT, ensuring its relevance and expansion in the coming years.

Key Attributes:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/8cg2rs

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Visit link:
Global Hormone Replacement Therapy Research Report 2024: A $35+ Billion Market by 2032 - Industry Trends, Share ... - GlobeNewswire

Posted in Hormone Replacement Therapy | Comments Off on Global Hormone Replacement Therapy Research Report 2024: A $35+ Billion Market by 2032 – Industry Trends, Share … – GlobeNewswire